No Data
No Data
Vicarious Surgical to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Encision Signs Master Services Agreement With Vicarious Surgical Inc.
Morgan Stanley Maintains Vicarious Surgical(RBOT.US) With Hold Rating, Cuts Target Price to $6.5
Morgan Stanley analyst Drew Ranieri maintains $Vicarious Surgical(RBOT.US)$ with a hold rating, and adjusts the target price from $10 to $6.5.According to TipRanks data, the analyst has a success
Piper Sandler Maintains Neutral on Vicarious Surgical, Adjusts Price Target To $12 From $30 (1-for-30 Reverse Stock Split)
Vicarious Surgical Analyst Ratings
Vicarious Surgical | 10-Q: Q2 2024 Earnings Report